Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Gynecology
»
Breast Diseases
06. March 2026
Search
medline.ch
Breast Diseases
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Reproduction
Genital Diseases female
Infertility
Breast Diseases
Menopause
Pregnancy
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 10759
Articles 1 - 20 / 215175
Evaluating the effect of using a mobile app on the management of chemotherapy side effects and quality of life in breast cancer patients: Protocol for a randomized controlled trial.
J Educ Health Promot
Raei Mehneh M, Kimiafar K, Mousavi Baigi SF, Marouzi P, Shahidsales S, Sarbaz M.
PMID: 41788960 [PubMed]
Relationships between social support and resilience of breast cancer patients in Indonesia: A cross-sectional study.
J Educ Health Promot
Pulungan RM, Helda H, Wahyono TYM, Sutandyo N.
PMID: 41788944 [PubMed]
Correction: Adherence with hormonal therapy in women with breast cancer: a cross-sectional study in Medellin, Colombia.
Colomb Med (Cali)
PMID: 41788894 [PubMed - in process]
Fusion of genomic and pathological data for breast cancer detection using BCDNN.
Front Med (Lausanne)
Bilal A, Obidallah WJ, Wassan S, Albathan M, Almakki R, Alshaikh Z, Shafiq M.
PMID: 41788706 [PubMed]
Factors Influencing Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Retrospective Study Focusing on ER and HER-2 Status.
Int J Breast Cancer
Zhang Y, Qiu S, Wang X.
PMID: 41788672 [PubMed]
An exploratory serum metabolomics study for screening and staging of breast cancer.
Gynecol Endocrinol
Zou Y, Song D, Cai Y, Liang K, Fu J, Zhang H.
PMID: 41787748 [PubMed - in process]
Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors.
Cancer Biol Med
Shao D, Yu T, Xiao Y, Shao Z.
PMID: 41787716 [PubMed - as supplied by publisher]
Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.
Int J Cancer
Nordenskjöld AE, Ríos-Romero M, Dar H, Fornander T, Perez-Tenorio G, Fohlin H, Stål O, Tutzauer J, Lindström LS.
PMID: 41787605 [PubMed - as supplied by publisher]
Acceptance and commitment therapy improves the quality of life of breast cancer patients by reducing helplessness: a randomized controlled trial.
BMC Palliat Care
Song W, Shari NI, Abdullah MFILB, Hussin HB, Zhang R, Mansor NS.
PMID: 41787365 [PubMed - as supplied by publisher]
IL3RA identified as novel biomarker and therapeutic target for ER(+) breast cancer through plasma proteome-wide mendelian randomization and TCGA database analysis.
Clin Proteomics
Mei H, Zhang Z, Jiang N, Lu W, Chang L, Song Q, Li F.
PMID: 41787256 [PubMed - as supplied by publisher]
Application of treatment response assessment maps (TRAMs), based on delayed-contrast MRI for radiomic characterization of breast lesions.
Sci Rep
Daniels D, Cohen K, Last D, Sharabi S, Zuniga M, Lahat N, Faermann R, Halshtok O, Shalmon A, Samoocha D, Gotlieb M, Mardor Y, Sklair-Levy M.
PMID: 41787008 [PubMed - as supplied by publisher]
Prediction of Ki-67 expression in invasive breast cancer with dual-modality radiomics.
Sci Rep
Xu R, Lin Q, Zheng C, Fang W, Liu C, Lin J, Gao F, Zhang S, Ouyang Q, Zhou Y.
PMID: 41786866 [PubMed - as supplied by publisher]
Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using a Three-tier MRI Radiomics Model with Nested Cross-validation.
Acad Radiol
Li H, Huang W, Liang J, Huang S, Xu X, Shao B, Chen H.
PMID: 41786550 [PubMed - as supplied by publisher]
Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
Lancet Oncol
GBD 2023 Breast Cancer Collaborators.
PMID: 41785894 [PubMed - in process]
Impact of screening on late-stage breast cancer in the Netherlands: a population-based cohort study (2007-2016).
Breast
Lin Y, Sidorenkov G, Wang J, Greuter MJW, Houssami N, Dorrius MD, Siesling S, de Munck L, de Bock GH.
PMID: 41785742 [PubMed - as supplied by publisher]
Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer.
Breast
Liu X, Yin S, Li X, Nie J.
PMID: 41785741 [PubMed - as supplied by publisher]
The correlation between gut microbiota and sleep quality changes in breast cancer patients receiving postoperative chemotherapy: a longitudinal study.
J Psychosom Res
Wu M, Lai F, Dong H, Xia W, Zheng L, Tian L.
PMID: 41785683 [PubMed - as supplied by publisher]
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.
ESMO Open
Jhaveri K, Bidard FC, Kalinsky K, Neven P, Rugo HS, Tolaney SM, Litchfield LM, von Laue CC, Traore S, Sapunar F, Li Y, O'Shaughnessy J.
PMID: 41785668 [PubMed - as supplied by publisher]
Breast cancer risk in peri- and postmenopausal women with a history of hormonal contraceptive use: A narrative review.
Maturitas
Ferguson D, Fraker J, Sahni S, Vegunta S, David PS.
PMID: 41785643 [PubMed - as supplied by publisher]
Characteristics and management of women with a new breast cancer diagnosis after previous breast cancer in Australia and New Zealand.
Eur J Surg Oncol
Shepherdson M, Edwards S, Bochner M.
PMID: 41785548 [PubMed - as supplied by publisher]
Articles 1 - 20 / 215175
Page 1 of 10759
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy